Savara (NASDAQ:SVRA) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

Savara Inc. (NASDAQ:SVRA – Get Free Report)’s share price crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $4.88 and traded as high as $5.34. Savara shares last traded at $5.21, with a volume of 12,260,866 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on SVRA shares. Royal Bank Of Canada set a $10.00 price objective on Savara in a research note on Wednesday, October 7th. Citigroup restated a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. JPMorgan Chase & Co. started coverage on shares of Savara in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.29.

Get Our Latest Report on SVRA

Savara Stock Up 10.4%

The firm has a fifty day moving average price of $4.88 and a 200 day moving average price of $5.32. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -8.54 and a beta of 0.32. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.28.

Savara (NASDAQ:SVRA – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Sell-side analysts anticipate that Savara Inc. will post -0.68 EPS for the current fiscal year.

Institutional Trading of Savara

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quarry LP increased its stake in shares of Savara by 6,524.4% during the 3rd quarter. Quarry LP now owns 11,924 shares of the company’s stock worth $62,000 after purchasing an additional 11,744 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Savara during the 3rd quarter worth about $720,000. Marshall Wace LLP raised its holdings in Savara by 2.1% in the 3rd quarter. Marshall Wace LLP now owns 6,386,775 shares of the company’s stock valued at $32,956,000 after acquiring an additional 129,786 shares during the period. Nantahala Capital Management LLC boosted its stake in Savara by 2.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 7,137,159 shares of the company’s stock valued at $36,828,000 after purchasing an additional 160,349 shares during the period. Finally, Nan Fung Trinity HK Ltd. lifted its holdings in shares of Savara by 1,088.3% during the third quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after buying an additional 1,687,310 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Recommended Stories

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.